News Blog

The Entourage Effect in Mushrooms: Natural psilocybin may outperform syntheticA new study from the Hebrew University-Hadassah Medical Center has indicated that natural psilocybin extracts may demonstrate superior efficacy to synthetic psilocybin extracts. Recent years...

Psychedelics in 2024: a year for investmentFollowing several transformative milestones in psychedelics, coupled with a surge in biotech investment, 2024 is set to see a profound shift for the sector as investors turn their attention toward solutions in mental health....

UK advisory body issues rapid response on psychedelics for anxietyThe UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for anxiety disorders. The response is intended to inform...

Supporting psychedelic therapy with digital interventionsA new paper has described the development of a self-directed intervention that harnesses digital technologies for psychedelic preparation. Psychedelics cause considerable changes in consciousness, requiring...

Psilocybin therapy for end-of-life care supported by 79% of CanadiansA new survey has revealed that over 79% of Canadians support psychedelic-assisted therapy for existential distress at the end of life. People facing a terminal diagnosis often experience significant...

Unlocking the Healing Potential of Psychedelics: A Conversation with Dr. Gaetano Morellohttps://www.youtube.com/watch?v=hZAjlikBOk0 In the realm of medicine and mental health, exploration knows no bounds. Traditional treatments, while valuable, often fall short in...

Could Mushrooms Be the Drug to Finally Cure Eating Disorders?For young patients, lasting treatment can feel elusive. Psychedelics could change that. The first time Sophia Anderson tripped on psychedelic mushrooms, she was 16 years old. It happened in late 2020, in the...

Psilocybin therapy for end-of-life care supported by 79% of CanadiansA new survey has revealed that over 79% of Canadians support psychedelic-assisted therapy for existential distress at the end of life. People facing a terminal diagnosis often experience significant...

Filament Health Announces FDA Opening Of Investigational New Drug Application For Substance Use DisordersFilament Health CEO Ben Lightburn joined Steve Darling from Proactive to share some groundbreaking news. The U.S. Food and Drug Administration (FDA) has given its...

Maybe, just maybe, psychedelics are the “master key” for unlocking everything from blindness to stroke to anorexia If I told you psychedelics might help people with everything from depression to blindness to anorexia to autism to stroke, you might think that’s just...

Vital report explores employment in the psychedelics industry Psychedelics Today recently surveyed students and graduates of its 12-month intensive professional psychedelic certification programme, Vital, publishing its findings in The Emerging Psychedelic Workforce...

Europe to establish regulatory guidance on psychedelics in 2024 The European Medicines Agency (EMA) is set to hold a multi-stakeholder workshop on medical psychedelics in April 2024 to establish regulatory guidelines for the development and therapeutic use of...

Filament Health Completes The First Export Of Botanical Psilocybin To Australia Reset Mind Sciences Ltd. has received a shipment of PEX010, Filament’s botanical psilocybin drug candidate Vancouver, British Columbia, January 17, 2024 – Filament Health...

https://www.youtube.com/watch?v=hZAjlikBOk0 Dr. Morello NeoLumina Founder, Director and CEO is an accomplished naturopathic clinician and nutraceutical entrepreneur with over 30 years of experience. We go thru Gaetano's background, his take on psychedelics,...

Are Psychedelics the Future of Eating Disorder Treatment? The drugs have been shown to reduce depression and anxiety symptoms and make individuals more flexible in their thinking Sarah Kelley was 14 years old when she first started to feel an intractable need to...

Psilocybin May Help Some Who Battle Anorexia (HealthDay News) -- One dose of the hallucinogenic ingredient in "magic mushrooms" may help some people with anorexia move past their preoccupation with body image, an early study suggests. The study, of just 10 women with...

Psilocybin Shows Early Promise for Anorexia NervosaThe psychedelic psilocybin may have a role in the treatment of anorexia nervosa (AN), an eating disorder that is notoriously difficult and costly to treat. In a very small phase 1 trial of 10 women with AN, a single...

Can Psilocybin Treat Eating Disorders? A New Study Aims To Find OutNew research suggests psilocybin can help with treatment-resistant eating disorders. Body image can severely affect a person’s wellbeing, both physically and mentally, and researchers are close to...

First psilocybin trial for bipolar depression shows promising resultsThe first-ever psilocybin trial for treatment-resistant bipolar type II disorder has shown 80% of participants meeting remission criteria 12 weeks after treatment.   JAMA Psychiatry recently...

Mapping the effects of ketamine on the brainA new study has mapped the effects of ketamine on the brain, finding that repeated use over extended periods creates widespread structural changes in the brain’s dopamine system. The study found that repeated ketamine...

How psychedelics could help those living with alcohol use disordersAlcohol use disorders (AUD) are estimated to affect around 237 million people across the globe, with 3 million deaths each year attributed to the harmful use of alcohol. Despite this prevalence, there...

Meta-analysis highlights potential of psilocybin therapy for treatment-resistant depressionA scientific review and meta-analysis published in Psychiatry Research concludes that “well-designed phase III trials are urgently needed” to further examine the promising...

Psychedelic therapy programmes launch to address heartbreak, burnout and moreMindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges.  Led by and developed with leading...

Canada recommends launch of Veterans psychedelic research programmeA new report has been released by Canada’s Senate Subcommittee on Veterans Affairs – ‘The Time Is Now: Granting Equitable Access to Psychedelic Assisted Therapies’ – which recommends the launch of a...

Psilocybin analogue shows positive results in Phase 2 depression studyCybin has announced positive Phase 2 topline safety and efficacy data for its proprietary deuterated psilocybin analogue – CYB003 – for the treatment of major depressive disorder (MDD). Results from...

Short Wave Pharma: innovating eating disorder care with psychedelicsPsychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital. Short Wave...

Compass Pathways launches Phase 3 psilocybin trial in UKCompass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched. The trial will be carried out at multiple sites in the UK,...

Understanding variability in psychedelic treatment responsesThe US National Institute on Drug Abuse (NIDA) has earmarked $2 million in funding for psychedelic treatment research into Substance Use Disorder (SUD). NIDA will commit the funds to three to five awards with...

Filament Health targets substance use disorders with natural psychedelicsFilament Health Corp (OTCQB:FLHLF)'s diversified business model makes it one of the only psychedelics companies to be already generating revenue.   The Vancouver, British Columbia-based...

Psychedelics Offer A New Mode Of Grief Therapy, But There’s A CatchPsychedelics are used to seek insight during life — and help people accept death. More and more families mourning the loss of a loved one are turning to psychedelic-assisted psychotherapy...

Psilocybin for major depression trial shows positive resultsCybin Inc. has announced Phase 2 interim results for CYB003 – its proprietary deuterated psilocybin analogue – which it says has demonstrated positive results with a rapid reduction in symptoms of major...

Psilocin prodrug receives USPTO development approvalEnveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE) prodrug of...

Study to investigate psilocybin therapy for cancer-related depressionPsychedelic therapy company Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD) in patients...

Psychedelic research receives Young Investigator GrantsThe Brain & Behavior Research Foundation has announced it is awarding $10.2 million in Young Investigator Grants including for projects investigating psychedelics. The grants have been awarded to 150 promising...

Nine ways to integrate the psychedelic experience for lasting changeFollowing all the hype generated about the therapeutic powers of psychedelics by Michael Pollan’s 2018 book How to Change Your Mind and follow up 2022 Netflix series of the same title – millions are...

First patient enrolled in psilocybin trial for demoralisationDiamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization. The trial is enrolling 60...

A New Frontier For Psilocybin Therapy? Standardized but NOT Synthetic If you wanted to do clinical trials for psilocybin, you generally have two options: synthetic psilocybin (which has it's downsides) or whole dried mushrooms (also, has downsides). But what if there...

Clinical trial investigating psilocybin for opioid addiction approvedHealth Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for the treatment of opioid use...

European psychedelic initiative aims to impact education and regulationA new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and boost EU-funded research on...

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in ratsPsilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in...

Psilocybin might be effective for treatment-resistant depression even with ongoing SSRI use, study suggestsIn a new exploratory phase II clinical trial, a single dose of psilocybin, when used as an adjunct to ongoing SSRI treatment and combined with supportive...

Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research NesterLeading psychedelic drugs market players include Research Nester are COMPASS Pathways plc, Silo Pharma, Inc., Numinus Wellness Inc., Cybin Inc., Mind Medicine Inc., Jazz...

Filament Health Announces FDA Approval Of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010The University of Washington and the University of California, Los Angeles have been approved to study PEX010 in clinical trials for mental health...

New Study Shows Candy-Flipping Can Reduce Bad TripsA new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics. “Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive...

Eating Disorder Recovery: 12 Tips to Aid in the ProcessRecovering from an eating disorder can be a long journey. Treatments for eating disorders are complex and multifaceted, but recovery is possible.(1) Because eating disorders can lead to serious medical...

Otsuka Pharmaceutical agrees to buy Mindset PharmaThe acquisition has received approvals from the boards of directors of both companies. Otsuka Pharmaceutical has signed a definitive agreement to acquire drug discovery-based research and development company Mindset...

Filament Health Enters Exclusive Licensing Agreement With Neolumina Bioscience Inc Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced an exclusive global licensing agreement...

Psychedelics Research and Psilocybin Therapy From Congress to the Biden administration, there’s enthusiasm for the drugs’ ability to treat mental illness. There’s a new cause in Washington that’s uniting Republicans, Democrats and Biden health officials: psychedelics...

Psychedelics Research and Psilocybin Therapy FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010 The University of Washington and the University of California, Los Angeles have been approved to study...

Psychedelics Research and Psilocybin Therapy The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound...

Psychedelic Treatment for Eating DisordersUnlike most other mental health disorders that can be treated successfully by medication, eating disorders have not been found to be as responsive to traditional psychiatric medicines. Anorexia nervosa has one of the highest...